{"id":390920,"date":"2017-08-31T00:00:00","date_gmt":"2017-08-31T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfim0005-2017-biopharma-graft-versus-host-disease-niche-rare-disease-landscape-forecast-us-eu5-2017\/"},"modified":"2026-03-31T10:50:00","modified_gmt":"2026-03-31T10:50:00","slug":"nrlfim0005-2017-biopharma-graft-versus-host-disease-niche-rare-disease-landscape-forecast-us-eu5-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfim0005-2017-biopharma-graft-versus-host-disease-niche-rare-disease-landscape-forecast-us-eu5-2017\/","title":{"rendered":"Graft-Versus-Host Disease | Niche &#038; Rare Disease Landscape &#038; Forecast | US\/EU5 | 2017"},"content":{"rendered":"<p>Graft versus host disease (<abbr title=\"graft versus host disease\">GVHD<\/abbr>) is a potentially life-threatening complication of allogenic hematopoietic stem-cell transplants (<abbr title=\"hematopoietic stem-cell transplantation\">HSCT<\/abbr>s). The systemic inflammatory reaction is triggered by donor T cells\u2019 recognition of host cell antigens in nontarget tissue as foreign. Steroids have been the first-line therapy for decades for the prevention and treatment of\u00a0<abbr title=\"graft versus host disease\">GVHD<\/abbr>. Interviewed experts cite a need for better treatments for steroid-refractory patients, as well as better first-line and prophylactic treatments for\u00a0<abbr title=\"graft versus host disease\">GVHD<\/abbr>. Although development in this space has historically been slow, the pipeline for\u00a0<abbr title=\"graft versus host disease\">GVHD<\/abbr>\u00a0therapies is now robust. Here, we analyze\u00a0<abbr title=\"graft versus host disease\">GVHD<\/abbr>\u00a0patient populations, current therapies and medical practice, and the clinical and commercial opportunity for emerging therapies, including AbbVie\/Janssen\u2019s Imbruvica(ibrutinib), Mallinckrodt\u2019s UVADEX(methoxsalen solution), and Incyte\u2019s Jakafi (ruxolitinib).Leukotac (inolimomab) and Novartis\u2019s Jakafi (ruxolitinib).<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<p>How large is the\u00a0<abbr title=\"graft versus host disease\">GVHD<\/abbr>\u00a0population, and how will it change through 2026? What percentage of the\u00a0<abbr title=\"graft versus host disease\">GVHD<\/abbr>\u00a0population receives drug treatment?<\/p>\n<p>How is\u00a0<abbr title=\"graft versus host disease\">GVHD<\/abbr>\u00a0currently managed in the\u00a0<abbr title=\"Usher syndrome\">U.S<\/abbr>. and\u00a0<abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>\u00a0countries? How well does the\u00a0<abbr title=\"graft versus host disease\">GVHD<\/abbr>\u00a0pipeline align with unmet clinical needs in the space?<\/p>\n<p>What are the key drug targets in\u00a0<abbr title=\"graft versus host disease\">GVHD<\/abbr>? Which emerging therapies do experts consider most promising? If approved, how would emerging therapies affect the management of\u00a0<abbr title=\"graft versus host disease\">GVHD<\/abbr>? Which emerging drugs hold the greatest commercial potential?<\/p>\n<p>PRODUCT DESCRIPTION<\/p>\n<p>Niche &#038; Rare Disease Landscape &#038; Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390920","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-graft-versus-host-disease","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390920\/revisions"}],"predecessor-version":[{"id":576821,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390920\/revisions\/576821"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}